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Abstract
Background: Mucopolysaccharidosis type I (MPS I) results in significant disease burden and early treatment is
important for optimal outcomes. Recognition of short stature and growth failure as symptoms of MPS I among
pediatric endocrinologists may lead to earlier diagnosis and treatment.
Case presentation: A male patient first began experiencing hip pain at 5 years of age and was referred to an
endocrinologist for short stature at age 7. Clinical history included recurrent respiratory infections, sleep
apnea, moderate joint contractures, mild facial dysmorphic features, scoliosis, and umbilical hernia. Height
was more than − 2 SD below the median at all time points. Growth velocity was below the 3rd percentile.
Treatment for short stature included leuprolide acetate and recombinant human growth hormone. The
patient was diagnosed with MPS I and began enzyme replacement therapy with laronidase at age 18.
Conclusions: The case study patient had many symptoms of MPS I yet remained undiagnosed for 11 years
after presenting with short stature. The appropriate path to MPS I diagnosis when patients present with short
stature and/or growth failure plus one or more of the common signs of attenuated disease is described.
Improved awareness regarding association of short stature and growth failure with attenuated MPS I is
needed since early identification and treatment significantly decreases disease burden.
Keywords: MPS I diagnosis, MPS I signs and symptoms, Growth delay, Physician awareness, Early diagnosis,
Short stature
Background
Mucopolysaccharidosis type I (MPS I) is a life-threaten-
ing, autosomal recessive disease caused by deficiency of
α-L-iduronidase (IDUA), a lysosomal enzyme respon-
sible for metabolizing the glycosaminoglycans (GAGs)
dermatan and heparan sulfate [1]. MPS I has an esti-
mated incidence of 1/100,000 live births with a spectrum
of phenotypes that range from severe (Hurler syndrome)
to attenuated (Hurler-Scheie and Scheie syndromes) dis-
ease, depending on neurocognitive involvement and the
rate of disease progression [2–4].
MPS I results in significant disease burden, disability,
and premature death from respiratory and cardiac
disease if left untreated, as well as neurodegeneration in
the severe phenotype [2]. Treatment options include en-
zyme replacement with laronidase (recombinant human
IDUA; Aldurazyme®) for patients with attenuated MPS I
[5–8] and hematopoietic stem cell transplantation
(HSCT), with or without laronidase, for patients with
severe MPS I [9–13]. Treatment outcomes depend on
phenotype and age at initiation of treatment [6, 14, 15].
Early treatment, prior to irreversible damage, can delay,
stabilize, or prevent disease, and is associated with sub-
stantially improved patient outcomes [5, 6, 10, 16–22].
Unfortunately, there may be considerable delays in the
diagnosis of MPS I, especially for patients with attenu-
ated disease [16, 23–25]. In a study of the diagnostic
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history of MPS I patients, approximately 20% of a popu-
lation of 60 patients with attenuated MPS I had delays
of 5 years or longer in diagnosis, and consulted between
4 and 5 specialists before receiving an MPS I diagnosis
[25]. Similarly, for 18 patients with MPS I (13 of whom
had attenuated disease) whose symptoms were noted at
18 months, the mean age at biochemical diagnosis was
75 months [26]. While pilot programs for MPS I NBS
are in progress around the world [27], they are not
universally available, and diagnostic delay persists. There
has been no significant improvement in reducing the
delay in diagnosis of MPS I as of 2017 [28]. Thus, it
remains likely that children with undiagnosed MPS I will
be referred to specialists, including endocrinologists, for
their care, and awareness of the early clinical signs and
symptoms remains important.
Short stature and skeletal sequelae known as dysosto-
sis multiplex are key features among patients with MPS
I [15, 24, 29–31], but MPS may be under recognized in
patients presenting with short stature, particularly in pa-
tients with attenuated disease. Regardless of age and gen-
der, children with MPS have severely disordered growth
with percentile values for both longitudinal and transver-
sal parameters (e.g., body length, trunk length, lower
extremity length, shoulder breadth, and hip breadth)
much lower than reference chart norms [32, 33].
Children with short stature (height less than 2 standard
deviations below the mean, i.e., near the third percentile)
and/or growth failure (growth rate below age-appropriate
growth velocity) are often referred to pediatric endocrinol-
ogists [34, 35]. While there are multiple monogenic causes
of short stature [35], attenuated MPS I should be consid-
ered in the differential diagnosis of patients with growth
retardation in conjunction with any of the signs and
symptoms of MPS I (Table 1), joint contractures, (particu-
larly of hands, with claw hand deformity, although other
joints can be affected), carpal tunnel syndrome (with
trigger digits), umbilical and inguinal hernias, corneal
clouding, hepatosplenomegaly, frequent respiratory
infections, sleep apnea, cardiac valve abnormalities, and
extensive surgical history. The constellation of radiologic
abnormalities of ribs, extremities and spine known as
dysostosis multiplex are more pronounced in severe MPS
I but can develop in patients with attenuated disease at a
later age. However, even patients with severe MPS I are
still misdiagnosed and treated for other disorders, such as
rickets [36], while patients with attenuated disease can go
undiagnosed or misdiagnosed [37, 38].
A real-world case report is presented to highlight the
existence of undiagnosed MPS I patients in pediatric
endocrinology clinics, and describe the appropriate path
to MPS I diagnosis when patients present with short
stature and/or growth failure plus one or more of the
common signs of attenuated disease as described in
Table 1 and Fig. 3.
Case presentation
A male patient first began experiencing hip pain at
5 years of age and was diagnosed with bilateral
Legg-Calve-Perthes disease by an orthopedic surgeon
(see Table 2 Timeline). The patient was not tested for
juvenile idiopathic arthritis. The patient experienced
recurrent upper airway tract infections during childhood
and was hospitalized multiple times between 5 and
7 years of age for wheezing. He was first seen by a
pediatric endocrinologist at 7 years of age due to his
short stature, was treated with leuprolide acetate
(3.75 mg/month) between the ages of 13 and 16 years,
and recombinant human growth hormone (0.1UI/kg/
day), although the patient was not labeled as growth
hormone deficient (GHD), between 14 and 18 years of
age. Longitudinal growth curves and growth velocity for
the patient between the ages of 10 and 21 are shown in
Figs. 1 and 2. Height was more than − 2 SD below the
median at all time points. Growth velocity was below
the 3rd percentile prior to starting growth hormone.
Final height of 159 cm was reached at 20 years of age.
The patient experienced sleep apnea throughout his
teenage years, and at 17 years 9 months of age was
referred to a metabolic disease center by a pneumologist
(pulmonologist) who had seen the patient and suspected
MPS. Upon examination, the patient was found to have
moderate joint contractures, mild facial dysmorphic
features (coarsening of features), scoliosis, and an umbil-
ical hernia. His height at examination was 154 cm, with
a z-score of − 2.94. Weight was 43.7 kg, and head
circumference was 56.5 cm. Alpha-iduronidase activity
on dried blood spot testing was 0.62 μmol/L/h (normal
reference range 2.5–16.7), and genotype analysis revealed
2 pathogenic IDUA missense variants, c.1148G >A
(p.R383H) and c.1598C >G (p.P533R), confirming the
Table 1 Common presenting/early symptoms in patients with
attenuated MPS I [24, 51]
• Growth delay (normal birth weight, but growth failure or short stature)
• Joint contractures (primarily in hands/claw hand deformity), joint pain
and stiffness, restricted mobility
• Carpal tunnel syndrome (trigger digits)
• Recurrent hernias (umbilical and/or inguinal)
• Corneal clouding
• Hepatosplenomegaly
• Skeletal abnormalities/dysostosis multiplex (e.g., kyphosis, scoliosis, hip
dysplasia, flattened vertebral bodies, oar-shaped ribs, short thickened
clavicles, bullet-shaped phalanges, dysplastic femoral heads, flattened
acetabula, coxa valga and genu valgum deformities)
• Ear/nose/throat symptoms (recurrent ear infections, noisy breathing,
sleep apnea, enlarged tongue, hearing loss)
• Heart murmur (valve abnormalities)
• Surgical history of multiple hernia repairs, PE tubes, tonsillectomy,
adenoidectomy
All symptoms may not be present in the same patient, but are usually
progressive. See Fig. 2 for the path to diagnosis
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diagnosis of MPS I. The patient began ERT with laroni-
dase (0.58 mg/kg/week) at age 18.
Discussion and conclusions
The case study demonstrates that endocrinologists may
not consider MPS I in cases of short stature, even when
there are signs and symptoms suggestive of MPS I.
Red-flag signs and symptoms for attenuated MPS I
(Table 1) exist in the absence of parameters indicating
juvenile idiopathic arthritis [39, 40]. The case presenta-
tion highlights the diagnostic journey of a patient with
attenuated MPS I and short stature followed for over
10 years in a pediatric endocrinology clinic. A strength
of this case is the duration of care and longitudinal
growth data, although in some instances, assessments
and clinical management information were unavailable.
This patient had many of the signs and symptoms of
attenuated MPS I, yet was not diagnosed until nearly
11 years after presenting to the pediatric endocrinologist
with short stature. While not all of the signs listed in
Table 1 may be apparent at the initial patient presenta-
tion to the endocrinologist, they are likely to develop
over time when untreated, or be documented in patient
clinical records and history. It is important to note that
assessment of bone age in children with growth delay is
typically done with an X-ray of the left hand and wrist;
thus, pediatric endocrinologists are ideally situated to
identify early phalangeal abnormalities (i.e., bullet shaped
phalanges) typical of MPS I. A path to MPS I diagnosis
when indicating signs are present is shown in Fig. 3.
Table 2 Timeline of assessments, diagnoses and treatment
Patient age Symptom(s) Assessments/diagnoses Treatment(s)
5–7 years Hip pain, recurrent respiratory
infections
Orthopedist assessment and diagnosis of
bilateral Legg-Calve-Perthes disease
unknown
7–18 years Short stature: see Figs. 1 and 2 Pediatric endocrinologist assessment Leuprolide acetate (3.75 mg/month)
ages 13–16
Growth hormone (0.1UI/kg/day) ages 14–18
18 years Short stature, moderate joint
contractures, mild facial dysmorphic
features (coarsening of features),
scoliosis, and an umbilical hernia
Referred to metabolic disease center by
treating pulmonologist.
enzyme activity screening for MPS I positive;
genetic analysis positive for MPS I
Enzyme replacement therapy with
laronidase (weekly 0.58 mg/kg infusions)
initiated
Fig. 1 Longitudinal Growth for Patient with Attenuated MPS I from Case Study. Height of case study patient by age is shown by the blue
markers with timing and duration of leuprolide acetate, growth hormone and laronidase treatments indicated. WHO Child Growth Standards
are indicated
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There is considerable overlap of presenting symptoms
among the MPS disorders, therefore, screening identified
in Fig. 3 should take into account other MPS disorders
where short stature is common. Upon consideration of
an MPS disorder, a urine GAG (uGAG) test (that may
include analyses to determine abnormal GAG pattern,
such as electrophoresis or tandem mass spectrometry)
can determine the presence of lysosomal storage mater-
ial. Results of the uGAG test as indicated in Fig. 3 can
warrant referral to a geneticist or metabolic disease spe-
cialist, who can initiate appropriate enzyme and genetic
testing to confirm or rule out an MPS diagnosis. Several
Fig. 2 Growth Velocity of Patient with Attenuated MPS I from Case Study Relative to Growth Standards. Growth velocity by age is shown by the
blue markers with timing and duration of leuprolide acetate (L), growth hormone (GH) and laronidase (LAR) treatments indicated. Treatment
doses are the same as shown in Fig. 1. Percentiles for boys maturing at average time or for late maturers are shown as adapted from Tanner JM
and Davies PS. Clinical longitudinal standards for height and height velocity for North American children [50]
Fig. 3 Symptom Checklist and Path to MPS I Diagnosis. The algorithm describes the key symptoms of MPS I and the pathway of diagnostic tests
for a patient presenting with short stature or growth delay
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barriers can exist for appropriate referrals of pediatric
patients to metabolic specialists and geneticists, includ-
ing cost and insurance, wait times, and location [41, 42]
and improvements in accessibility for lysosomal storage
disease assays may be needed [43].
Studies suggest that increased awareness for endocri-
nologists may be helpful to highlight the possibility of
attenuated MPS in patients presenting with short stature
[37, 38]. In a retrospective assessment of outpatient
medical records of patients with short stature of
unknown etiology in a pediatric endocrinology service,
follow-up screening of 23 patients revealed previously
undiagnosed MPS in 3 patients [37]. In another study,
135 physicians with expertise in pediatrics and endocrin-
ology from seven countries (United States, Canada, Italy,
Germany, Spain, Mexico, and Brazil) participated in a
blinded review of cases for pediatric or adolescent pa-
tients with MPS I [38]. Depending on the case reviewed,
only 22% to 58% of physicians took steps towards a
correct MPS I diagnosis. Juvenile idiopathic arthritis was
the most common incorrect diagnosis made. A key
distinction in the diagnosis of MPS I is the absence of
biochemical parameters diagnostic of juvenile idiopathic
arthritis. While algorithms exist that include MPS I in
the differential diagnosis of juvenile arthritis for pediatric
rheumatologists [39, 40], growth specialists and endocri-
nologists may be among the physicians encountering
individuals with undiagnosed MPS disorders, and similar
guidelines could prove helpful for recognizing the
red-flag signs and symptoms of MPS I and other MPS
disorders. A proposed algorithm that includes short stat-
ure as a presenting sign in attenuated MPS I has recently
been published [44].
The mechanism behind short stature in patients with
MPS I is not completely known, but is most likely a
secondary characteristic resulting from structural, meta-
bolic, and endocrine abnormalities. Structurally, skeletal
abnormalities limit longitudinal growth and final height,
but alone cannot explain short stature in patients with
MPS I. Pituitary and thyroid dysfunction, GHD, preco-
cious puberty, and pubertal failure have all been re-
ported in patients with MPS I [32, 45]. However, it is
important to note that in the absence of GHD, hGH
treatment of patients with MPS has not been proven to
be effective.
Enzyme replacement therapy with laronidase has re-
sulted in increased growth velocity in pediatric patients
[46], particularly in prepubescent children with MPS I
[20]. In sibling studies, improved musculoskeletal out-
comes were noted in the younger sibling who began
ERT in infancy [5, 18, 19]. Retrospective studies indicate
that early initiation of laronidase can stabilize existing
skeletal disease, and prevent or delay clinical manifesta-
tions if initiated prior to symptom onset [5, 19–22].
Patients with attenuated MPS I that were less than 10 years
of age at treatment initiation remained closer to
age-matched norms for several disease parameters, includ-
ing height, compared with patients that were ≥ 10 years of
age at the start of treatment [22]. There is disagreement
regarding the benefits of administration of recombinant
human growth hormone, and this is an area of active
study [47].
In summary, short stature is a common presenting
sign of attenuated MPS I, and may be the symptom that
drives clinical care in these patients [36, 48, 49]. Since
pediatric endocrinologists are typically the first physician
to whom patients with short stature are referred [35],
they can play a pivotal role in improving the health and
quality of life of patients with attenuated MPS I. Early
diagnosis of MPS I and initiation of treatment is
critically important as it improves patient outcomes and
reduces disease burden [5, 6, 8, 19, 22]. MPS I should be
considered in any patient with short stature and/or
growth failure plus one or more of the common signs
described in Table 1. The path to diagnosis (Fig. 2)
includes urine GAG test, referral to geneticist (or meta-
bolic disease specialist), and appropriate enzyme and
genetic testing. Improving the ability of pediatric
endocrinologists to recognize the disease manifestations
of MPS I can lead to earlier diagnosis and treatment for
individuals with MPS I.
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